PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Pulmonary Therapy2 citationsOpen Access

Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis

CHCarina M. E. HansenBZBadr ZendakyAZAnnelies M. Zwitserloot

Key Points

  • To evaluate long-term adherence to Elexacaftor/Tezacaftor/Ivacaftor (ETI) and Ivacaftor (IVA) in patients with cystic fibrosis.
  • Analyzed pharmacy refill data over three years
  • Monitored adherence to ETI and IVA
  • Calculated adherence rates at multiple time points
  • High adherence to ETI and IVA observed initially
  • Adherence levels declined over the three-year period
  • Refill data indicated consistent patterns of medication usage

Abstract

Three-year adherence to ETI and IVA based on pharmacy refill data was high, yet declined over time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hansen et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc44b39f7826a300d131https://doi.org/10.1007/s41030-026-00351-4
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P057 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) aged 6–11 years – the RECOVER study2024 · 2 citations
  2. 2The impact of medication adherence on lung health outcomes in cystic fibrosis2013 · 72 citations
  3. 3What We Mean When We Talk About Adherence in Respiratory Medicine2016 · 140 citations
  4. 4A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes2018 · 263 citations
  5. 5Pulmonary medication adherence among children and adults with cystic fibrosis: Is there an association with disease severity?2022 · 6 citations